BIVIW公司概覽
盤中時間採用ET。市場資料可能有所延遲。
公司概況
公司網站BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
- 產業
- Biotechnology
- 部門
- Healthcare
- 總部
- US
- 執行長
- Cuong Viet Do
- 上市以來
- 2026年7月17日
- 僱員
- 13
市場位置
日內區間
目前US$0.26
52週區間
目前US$0.26
- 開盤價
- US$0.23
- 前收盤價
- US$0.25
- 成交量
- 634
- 0.01× 平均值
- 平均成交量
- 7.68萬
- 日均成交量
- 市值
- 221.81萬 USD
- 貝塔
- 0.3
- 市場參考 1
- 50天平均值
- US$0.3092
- 低於平均水平-15.90%
- 200天平均值
- US$0.3092
- 低於平均水平-15.90%
